Adocia obtains additional financial resources from IPF Partners for a maximum amount of €15m

Adocia SA, a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, today announced that it has obtained additional resources from IPF Partners to finance its growth.